September 26, 2025

Movi, together with its international partner Tandem Diabetes Care, presented today in Rome to an audience of approximately 200 participants—including healthcare professionals, industry associations, and patient advocates—the latest innovations transforming the daily management of diabetes. The event marks a significant step forward in technological solutions for the treatment of type 1 diabetes.

The meeting, titled “Moving Borders in Diabetes Care – Technology Shaping Change,” brought together experts, clinicians, and the commercial team of Movi’s Biosystem Business Unit to share the latest advancements, all aimed at a clear goal: simplifying diabetes management and improving the quality of life for people living with the condition.

The new developments focus on the Tandem t:slim X2 system with Control-IQ technology: a hybrid closed-loop system, already widely used in Italy, that combines an insulin pump, a continuous glucose monitoring sensor, and an algorithm that automatically adjusts basal insulin delivery and delivers automatic correction boluses based on blood glucose levels prediction.

Four innovations, a single integrated system

The new features unveiled today in Rome by Movi and Tandem Diabetes Care outline an increasingly comprehensive and flexible ecosystem that puts the patient at the center, supports healthcare providers, and makes diabetes management even simpler and more effective. Here are the main new features:

• Tandem t:slim Mobile App – allows patients to manage their insulin therapy (including bolus delivery) directly from an app downloaded on their smartphone, offering greater autonomy, discretion, and treatment adherence.
• Tandem Source – a new proprietary web platform that enables automatic synchronization of data collected by the system and the sensor with the cloud, making data exchange faster and more seamless between patients and healthcare professionals, and improving clinical efficiency.
• FreeStyle Libre 3 Plus – an additional CGM sensor compatible with the Tandem t:slim X2 insulin pump, joining the Dexcom G6 and G7, expanding treatment options and personalization.
• Control-IQ+ – a new advanced algorithm that introduces greater flexibility, allowing users to set temporary basal profiles and extended boluses lasting up to eight hours, even during automatic insulin modulation. This makes the system now accessible to children as young as 2 years old and to patients with very low or very high insulin requirements.

A revolution for patients and healthcare professionals

“These innovations, the result of a strong partnership with Tandem Diabetes Care, represent a major advancement for the entire type 1 diabetes management ecosystem. This is a true game-changer, both for patients and healthcare professionals,” says Enrico Ceribelli, Director of the Biosystem Business Unit at Movi SpA. “For us at Movi, innovation means ensuring greater freedom and safety for patients, while offering clinicians more efficient and intuitive tools that simplify clinical practice. This is our revolution: a new system that supports both doctors and patients by making diabetes management simpler and more effective.”

The innovations presented reinforce the role of the Tandem t:slim X2 system with Control-IQ technology as one of the few Advanced Hybrid Closed Loop (AHCL) systems capable of automating not only basal insulin delivery but also corrective boluses. The addition of remote management via app and compatibility with multiple CGM sensors represents a major step forward toward a fully integrated ecosystem.